Biotricity Inc. BTCY
We take great care to ensure that the data presented and summarized in this overview for BIOTRICITY INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BTCY
View allLatest Institutional Activity in BTCY
Top Purchases
Top Sells
About BTCY
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Insider Transactions at BTCY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 29
2021
|
Norman M. Betts Director |
BUY
Grant, award, or other acquisition
|
Direct |
54,348
+12.64%
|
-
|
|
Nov 29
2021
|
David A Rosa Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,174
+15.15%
|
-
|
|
Oct 11
2021
|
David A Rosa Director |
SELL
Open market or private sale
|
Direct |
3,318
-2.59%
|
$9,954
$3.05 P/Share
|
|
Oct 08
2021
|
David A Rosa Director |
SELL
Open market or private sale
|
Direct |
9,481
-6.88%
|
$28,443
$3.2 P/Share
|
|
Oct 07
2021
|
David A Rosa Director |
SELL
Open market or private sale
|
Direct |
17,228
-11.11%
|
$51,684
$3.08 P/Share
|
|
Sep 16
2021
|
David A Rosa Director |
SELL
Open market or private sale
|
Direct |
34,977
-18.41%
|
$104,931
$3.43 P/Share
|
|
Sep 15
2021
|
David A Rosa Director |
SELL
Open market or private sale
|
Direct |
6,246
-3.18%
|
$18,738
$3.27 P/Share
|